HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.

CONCLUSIONS: HOXA4/HOXB3 gene expression-based risk score may be useful for prognostic risk stratification and warrants prospective validation in HGSOC patients. PMID: 29402501 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29402501?dopt=Abstract

Source: Gynecologic Oncology - February 2, 2018 Category: Cancer & Oncology Authors: Miller KR, Patel JN, Zhang Q, Norris EJ, Symanowski J, Michener C, Sehouli J, Braicu I, Destephanis DD, Sutker AP, Jones W, Livasy CA, Biscotti C, Ganapathi RN, Tait DL, Ganapathi MK Tags: Gynecol Oncol Source Type: research